NCT01089101 2026-03-18
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Gustave Roussy, Cancer Campus, Grand Paris